Heskamp, Sandra <br/><br/>
Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression.  [electronic resource] 

 -  Molecular pharmaceutics  Nov 2014 
 - 4249-57 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1543-8392 
<br/><br/><label>Standard No.: </label>10.1021/mp500460g  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Breast Neoplasms--drug therapy<br/>Cetuximab<br/>Enzyme-Linked Immunosorbent Assay<br/>ErbB Receptors--metabolism<br/>Female<br/>Humans<br/>Immunoenzyme Techniques<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Molecular Targeted Therapy<br/>Multimodal Imaging<br/>Tumor Cells, Cultured<br/>Vascular Endothelial Growth Factor A--metabolism<br/>Xenograft Model Antitumor Assays